Trial
NCT04767698
Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Johns Hopkins University
Collaborators
GlaxoSmithKline
Condition
Multiple Sclerosis
Intervention
Belimumab
Why stopped
The funding source decided to stop funding the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-07